536 articles|Clear filters
WT1 molecular assessment combined with flow cytometry increases the prognostic value of pre transplant MRD in AML
The presence of Minimal Residual Disease (MRD) before allogeneic Stem Cell Transplantation (SCT) has been shown to be associated with poor outcomes…
Cynthia Umukoro , May 18, 2017
The impact of abnl(17p) on the outcomes of AML patients receiving allogenic HSCT – A Japanese study.
Acute Myeloid Leukemia (AML) patients with abnormalities in the short arm of chromosome 17 (abnl[17p]) have been reported to have poor outcomes after…
The FDA grants CD33-specific CAR+ T cell Investigational New Drug Application clearance for treatment of R/R AML
On 2nd May 2017, the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application and granted clearance for…